MAD2L1 (Mitotic Arrest Deficient 2-Like 1) is a critical component of the mitotic spindle assembly checkpoint (SAC), a surveillance mechanism ensuring accurate chromosome segregation during cell division. This protein acts as a sensor of unattached kinetochores, delaying anaphase onset until all chromosomes are properly aligned. Dysregulation of MAD2L1 is linked to chromosomal instability, a hallmark of cancer and genetic disorders.
MAD2L1 antibodies are essential tools for studying SAC function, protein localization, and expression dynamics in mitotic processes. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate MAD2L1’s role in cancer progression, drug resistance, and response to anti-mitotic therapies. Elevated MAD2L1 levels are observed in various cancers (e.g., breast, lung, colorectal), correlating with poor prognosis, while reduced expression may impair checkpoint signaling, promoting aneuploidy.
These antibodies also aid in exploring MAD2L1’s interaction with other checkpoint proteins (e.g., BUBR1. CDC20) and its involvement in pathological conditions beyond cancer, such as autoimmune diseases and neurodegeneration. Researchers utilize MAD2L1-targeting antibodies to validate experimental models (e.g., knockout cells) and assess therapeutic interventions targeting mitotic checkpoints.